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Abstract Schistosoma mansoni receptor kinase-1 (SmRK1) is a
divergent type I transforming growth factor L (TGFL) receptor
on the surface of adult parasites. Using the intracellular domain
of SmRK1 as bait in a yeast two-hybrid screen we identified an
interaction with S. mansoni 14-3-3O. The interaction which is
phosphorylation-dependent is not specific to schistosomes since
14-3-3O also binds to TLRI, the human type I TGFL receptor. 14-
3-3O enhances TGFL-mediated signaling by TLRI and is the first
TLRI-interacting non-Smad protein identified that positively
regulates this receptor. The interaction of 14-3-3O with schisto-
some and human TLRI suggests a conserved, but previously
unappreciated, role for this protein in TGFL signaling
pathways. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Schistosoma mansoni receptor kinase-1 (SmRK1) is a diver-
gent member of the receptor serine threonine kinase (RSTK)
family [1]. Mammalian members of the RSTK family are re-
ceptors for the transforming growth factor L (TGFL) family
of ligands, which includes TGFL’s, activins, bone morphoge-
netic proteins (BMPs) and other factors that play prominent
roles in governing growth and development. TGFL receptors
are classed as type I or type II (TLRI or TLRII) based on
functional and structural characteristics [2]. Both TLRI and
TLRII have a short cysteine-rich extracellular domain, a single
transmembrane domain and an intracellular serine/threonine
kinase domain. TLRIs are characterized by a highly conserved
GS domain; a repetitive glycine^serine motif which is phos-
phorylated on activation. TLRIIs have a serine/threonine-rich
C-terminus, are constitutively active and are responsible for
ligand binding [2]. SmRK1 has previously been characterized
as TLRI [1]. S. mansoni, a parasitic trematode, is the earliest
diverging organism in which a member of the TGFL receptor
family has been identi¢ed.
Transduction of signal by RSTKs requires the ligand-medi-
ated formation of a heteromeric complex between receptors I
and II. TGFL ligands can give rise to multiple outcomes in
cells but the precise mechanisms by which all of the pleiotro-
pic e¡ects are mediated remain incompletely understood. In
the most well characterized signaling pathway, TLRI, acti-
vated through phosphorylation by TLRII, phosphorylates
Smad proteins which mediate signal transduction by translo-
cation to the nucleus and alteration of gene expression to elicit
the speci¢c ligand response (reviewed in [3]). However, it is
becoming increasingly clear that other pathways can be en-
gaged by RSTKs. For example, both TGFL and BMP can
initiate activation of TGFL-activated kinase, a MAPKKK
(mitogen-activated protein kinase kinase kinase), with resul-
tant activation of JNK and p38 kinases [4,5]. Members of the
Ras and Rho families of small GTP-binding proteins have
also been implicated in TGFL signaling and certain MAPKs,
such as ERK1 and SAPK-JNK, are activated by TGFL in
certain cell types [6,7]. These observations demonstrate the
existence of cross talk between TGFL receptors and multiple
signaling pathways. However, in most cases the molecular
mechanisms which link the TGFL receptors and elements of
these signaling cascades remain poorly de¢ned.
As little is known about TGFL signaling in S. mansoni, we
used the yeast two-hybrid assay to identify proteins that in-
teract with the intracellular domain of SmRK1. One of the
clones identi¢ed encoded S. mansoni 14-3-3O, which was
shown to bind SmRK1 in vitro. This interaction is su⁄ciently
conserved to cross species, since S. mansoni 14-3-3O binds
human TLRI both in vitro and in vivo. The functional con-
sequence of this interaction is enhanced TGFL-mediated sig-
nal transduction by TLRI. With the exception of Smads, 14-3-
3O is the ¢rst TLRI-interacting protein shown to activate sig-
naling by this receptor.
2. Materials and methods
2.1. Two-hybrid assay in yeast
An adult S. mansoni cDNA library was screened with an intracel-
lular domain of SmRK1 (amino acids (aa) 168^594), fused in-frame to
the 3P end of the DNA-binding domain of LexA. Saccharomyces ce-
revisiae EGY48 was ¢rst transformed with the reporter plasmid
p8opLacZ, then subsequently co-transformed with the bait plasmid
pLexA^SmRK1 and the cDNA library in pB42AD expression vector
(Clontech). Positive co-transformants were selected on synthetic drop-
out (SD galactose/ra⁄nose^Leu^His^Trp^Ura) plates, and con¢rmed
by detection of L-galactosidase activity on plates with X-GAL. Can-
didate plasmids puri¢ed from yeast were sequenced by the dideoxy
method.
2.2. Isolation of 14-3-3O and sequence analysis
One positive clone encoded a fragment of DNA (115 bp) with
homology to 14-3-3 proteins. The 14-3-3 sequence was completed by
polymerase chain reaction (PCR) ampli¢cation of S. mansoni cDNA
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library in pB42AD, using a 5P pB42AD primer and a 3P 14-3-3-speci¢c
primer. The resulting PCR product was sub-cloned into PCRII (In-
vitrogen) and subjected to DNA sequencing. Full length 14-3-3O was
PCR ampli¢ed from S. mansoni ¢rst strand cDNA, sub-cloned into
PCRII and re-sequenced for accuracy. PCR ampli¢cation of mouse
cDNA using 14-3-3O-speci¢c primers yielded no bands, demonstrating
that the 14-3-3O identi¢ed was of schistosome origin and not a mouse
gene contaminant of the S. mansoni cDNA library. S. mansoni 14-3-3O
was assigned GenBank accession number AF195529.
2.3. Expression plasmids
14-3-3O was cloned into the BamHI and XhoI sites of pGEX-4T-l
(Amersham Pharmacia Biotech). The N-terminal FLAG-tagged 14-3-
3O (pCMV2-14-3-3O-FLAG) was generated by sub-cloning at NotI
and BamHI sites into pCMV2 FLAG (Sigma). HA-tagged TLRI
(pCMV5-TLRI-HA) and His-tagged TLRII (pCMV5-TLRII-His),
provided by Dr. J. Massague, were used for PCR ampli¢cation of
receptor intracellular domains. The intracellular domains of SmRK1
(aa 168^594) TLRI (aa 151^503) and TLRII (aa 195^567) were PCR
ampli¢ed with primers placing an ATG within a Kozak consensus
sequence at the 5P end, and sub-cloned into PCRII plasmid.
2.4. In vitro interaction studies
Glutathione S-transferase (GST) and GST^14-3-3O fusion proteins
were produced from pGEX-4T-l-transformed bacteria, and bound to
glutathione^Sepharose 4B beads as described [8]. The PCRII plasmids
encoding the receptors were transcribed from the T7 promoter, trans-
lated and 35S-labeled using the TNT rabbit reticulocyte lysate kit
(Promega). 35S-Labeled receptors were added to glutathione^Sephar-
ose bound to either GST or GST^14-3-3O in a total volume of 500 Wl
TNEN bu¡er (20 mM Tris^HCl, pH 8.0, 100 mM NaCl, 1 mM
EDTA, 0.5% NP40) and incubated for 2 h at 4‡C. Following adsorp-
tion the beads were washed and subjected to SDS^PAGE followed by
£uorography to detect speci¢cally bound 35S-labeled receptor protein.
35S-Labeled SmRK1 was de-phosphorylated by incubating with 50 U
alkaline phosphatase (AP; Gibco) at 30‡C for either 15 or 60 min.
2.5. Co-immunoprecipitation
COS-7 cells were plated at 2U105 cells/well of six-well plates 18^24
h prior to transient transfection with lipofectamine (Gibco) and either
pCMV2-14-3-3O-FLAG (1 Wg DNA/well) alone, or in combination
with PCMV5-TLRI-HA or PCMV5-TLRII-His (1 Wg total DNA/
well). 48 h post-transfection, cells were harvested in lysis bu¡er (20
mM Tris^HCl, pH 7.5, 150 mM NaCl, 0.5% Triton X-100) containing
50 mM sodium £uoride and 1 mM sodium orthovanadate plus pro-
tease inhibitors. Following centrifugation, lysates were incubated with
anti-HA or anti-FLAG antibody at 4‡C overnight, followed by pro-
tein A Sepharose beads for 4 h. Following adsorption, beads were
washed with lysis bu¡er and subjected to SDS^PAGE followed by
transfer onto Immobilon P membrane (Millipore). Co-immunopreci-
pitated proteins were detected by immunoblot with either anti-FLAG
or anti-TLRII (Santa Cruz Biotechnology), followed by horseradish
peroxidase-conjugated secondary antibody and enhanced chemilumi-
nescence.
2.6. Functional assays
The R1B cell line, provided by Dr. J. Massague, is a mutant de-
rivative of mink lung epithelial cells which lacks TLRI [9]. R1B cells,
maintained in modi¢ed Eagle’s medium, containing 10% fetal bovine
serum, were plated at 1.5U105 cells/well of six-well dishes 18^24 h
prior to transfection. Cells were transfected using 0.3 Wg of expression
construct, 0.3 Wg reporter DNA, 0.1 Wg L-galactosidase construct for
normalization of transfection e⁄ciency and 3 Wl FuGENE 6 (Roche)
per well. Following overnight recovery, cells were serum-starved for
4 h, then incubated for 20 h in the presence of 500 pM TGFL (Gen-
zyme). At 48 h post-transfection, the cells were harvested in reporter
lysis bu¡er (100 mM KPO4 and 100 mM dithiothreitol). The lucifer-
ase activity of lysates was measured in a Berthold luminometer (Lu-
mat LB9501); L-galactosidase activity in the same lysates was ana-
lyzed using GalactoLight Plus (Tropix) and values were derived from
triplicate determinations.
3. Results
3.1. Identi¢cation of 14-3-3O through its interaction with
SmRK1 in the yeast two-hybrid assay and cloning of full
length sequence
To identify proteins that interact with SmRK1, an adult
S. mansoni cDNA library was screened in a yeast two-hybrid
assay using the intracellular domain of SmRK1 as bait. Of the
Fig. 1. Alignment of predicted amino acid sequence of S. mansoni 14-3-3O with mammalian and Drosophila 14-3-3Os. Sequences were aligned us-
ing the Clustal function of the MegAlign program (DNASTAR Inc.). GenBank1 accession numbers for the 14-3-3O sequences are S. mansoni,
AF195529; Xenopus, AAC41251; human, U43399; and Drosophila, P92177. Identical amino acids shared by all four proteins are shaded. Two
motifs characteristic of 14-3-3 family proteins are underlined. A double-headed arrow indicates the C-terminal region of S. mansoni 14-3-3O
identi¢ed in the two-hybrid screen.
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resulting 17 positive clones that interacted with SmRK1, one
encoded a protein with homology to 14-3-3 proteins. The
majority of the 16 remaining positive clones shared no identity
with known proteins; clones encoding protein interaction do-
mains have been selected for further study. The 14-3-3 clone
yielded a 115 bp DNA fragment with homology to the C-
terminus of 14-3-3s, and included an in-frame stop codon.
The remaining 14-3-3 sequence was obtained by primer exten-
sion, using 14-3-3- and vector-speci¢c primers in PCR ampli-
¢cation of the schistosome cDNA library. Full length S. man-
soni 14-3-3 ampli¢ed from ¢rst strand cDNA is 750 bp in
length and codes for a protein of 249 amino acids, with an
apparent molecular weight of 29 kDa. A search of GenBank1
using BLAST and comparison of the schistosome 14-3-3 with
other 14-3-3 sequences revealed maximum similarity with Dro-
sophila and mammalian 14-3-3O homologs (Fig. 1). The de-
duced amino acid sequence of schistosome 14-3-3 shares 65,
64 and 64% identity with Drosophila, Xenopus and human 14-
3-3O sequences, respectively. As our SmRK1-interacting 14-3-
3 has most identity with 14-3-3O family members, we termed it
S. mansoni 14-3-3O. The two signature motifs characteristic of
the 14-3-3 family of proteins are shown underlined in Fig. 1;
these sequences are identical in all four sequences.
3.2. 14-3-3O and SmRK1 interact directly in vitro in a
phosphorylation-dependent manner
To con¢rm the interaction detected in yeast we assessed the
ability of SmRK1 to interact with 14-3-3O in vitro. 35S-La-
beled SmRK1 interacted directly with 14-3-3O fused to GST,
but not to GST alone (Fig. 2, lane 1). 14-3-3 proteins bind
their target proteins at conserved binding sites containing a
phosphoserine or phosphothreonine residue that plays a key
role in the interaction [10,11]. SmRK1 does not contain any
previously described 14-3-3 binding site, therefore, we aimed
to determine whether phosphorylation of SmRK1 was impor-
tant for its interaction with 14-3-3O. 35S-Labeled SmRK1 was
treated with AP, and the ability of this de-phosphorylated
SmRK1 to interact with GST^14-3-3O was assessed (Fig. 2,
lanes 2 and 3). AP treatment of SmRK1 for 15 min resulted in
a greatly decreased level of SmRK1 association with GST^14-
3-3O as compared to untreated SmRK1, and when AP treat-
ment was increased to 1 h, the association of SmRK1 and
GST^14-3-3O was almost completely abrogated (Fig. 2, lane
3). This correlation between SmRK1 de-phosphorylation and
reduced binding to GST^14-3-3O suggests that the interaction
between SmRK1 and 14-3-3O is, at least in part, phosphory-
lation-dependent.
3.3. 14-3-3O interacts in vitro and in vivo with TLRI but not
TLRII
Since schistosome 14-3-3O has high homology with human
14-3-3O, and the intracellular domain of SmRK1 shares 53%
identity with this domain in TLRI, we sought to determine
whether the 14-3-3O^type I receptor interaction may be uni-
versal and species-independent. 35S-Labeled TLRI interacted
Fig. 2. Association of S. mansoni 14-3-3O and SmRK1 is dependent
on phosphorylation of SmRK1. 35S-Labeled SmRK1 intracellular
domain was untreated or treated with AP for 15 or 60 min and in-
cubated with glutathione^Sepharose-coupled GST (middle panel) or
GST^14-3-3O (bottom panel). Following washing, eluted and input
(top panel) proteins were analyzed by SDS^PAGE and £uorogra-
phy. The top panel shows 20% of the input 35S-labeled receptor
used in each of the adsorption experiments.
Fig. 3. Interaction of S. mansoni 14-3-3O with TLRI and TLRII in
vitro and in vivo. A: In vitro translated 35S-labeled TLRI and
TLRII intracellular domains were incubated with glutathione^Seph-
arose-coupled GST (middle panel) or GST^14-3-3O (right panel);
bound proteins were subject to SDS^PAGE and £uorography.
B: COS-7 cells were transfected with pCMV2-14-3-3O-FLAG alone,
or in combination with pCMV5-TLRI-HA (top panel) or pCMV5-
TLRII-His (bottom panel). Left panels show co-immunoprecipita-
tions (Co-IP) and right panels show portions of clari¢ed cell lysates
to determine expression levels of 14-3-3O and TLRII. Top: anti-HA
immunoprecipitates (IP) analyzed for the co-precipitation of 14-3-3O
by immunoblotting with anti-FLAG antibody. Bottom: anti-FLAG
immunoprecipitates analyzed for the presence of TLRII by immuno-
blotting with anti-TLRII antibody. The anti-TLRII antibody reacts
with auto-phosphorylated TLRII resulting in a laddered binding
pattern.
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directly with S. mansoni 14-3-3O fused to GST, but not to
GST alone (Fig. 3A). In contrast, the TLRII did not interact
with schistosome 14-3-3O (Fig. 3A). To determine whether this
in vitro interaction might also occur in vivo we performed co-
immunoprecipitation studies. FLAG-tagged 14-3-3O was ex-
pressed in COS-7 cells, alone or in combination with either
HA-tagged TLRI or His-tagged TLRII. An anti-HA immuno-
precipitation, which allowed puri¢cation of TLRI (data not
shown), was followed by an anti-FLAG immunoblot for
14-3-3O detection. 14-3-3O was speci¢cally co-precipitated by
TLRI, con¢rming the interaction detected in vitro (Fig. 3B,
top). In contrast, an anti-FLAG immunoprecipitation of
14-3-3O followed by an anti-TLRII immunoblot showed no
signi¢cant TLRII co-precipitation (Fig. 3B, bottom), demon-
strating that 14-3-3O interacts directly and speci¢cally with
TLRIs.
3.4. 14-3-3O enhances TGFL-mediated signaling by TLRI
To ascertain the functional relevance of the interaction be-
tween 14-3-3O and TLRIs we performed studies with the
TGFL-responsive reporter plasmid p3TP-Lux, which contains
elements from the PAI-1 promoter and drives expression of a
luciferase reporter gene [12]. R1B cells lack TLRI and are
unresponsive to TGFL [9]. Transfection of the cells with
TLRI restores responsiveness to TGFL (Fig. 4). In the absence
of TLRI, expression of S. mansoni 14-3-3O alone had no e¡ect
on luciferase activity. However, when TLRI and 14-3-3O were
co-expressed, a TGFL-induced increase in luciferase activity
was observed. This increase in activity is signi¢cantly more
than when the cells were transfected with TLRI alone and,
moreover, activity is enhanced in a 14-3-3O dose-dependent
manner (Fig. 4). These results suggest that 14-3-3O acts as a
positive regulator of transcription activity in response to
TGFL.
4. Discussion
We report the identi¢cation of the O isoform of 14-3-3 from
S. mansoni and show that it interacts with the type I RSTK,
SmRK1. Furthermore, 14-3-3O interacts with and enhances
TGFL-mediated signaling by TLRI, as measured by activation
of the p3TP-Lux promoter. The 14-3-3 family, which includes
nine highly homologous members in mammals (K, L, Q, N, O, R,
c, d and j), form dimers and are thought to function in a wide
range of signaling pathways by acting as molecular sca¡olds
or chaperones [13]. 14-3-3O has been reported as the isoform
most likely to have retained the characteristics of the ancestral
14-3-3 gene [14].
S. mansoni 14-3-3O, which shares 64% amino acid identity
with human 14-3-3O, binds to and enhances signaling by hu-
man TLRI. Conservation of 14-3-3 functionality across spe-
cies has previously been demonstrated in yeast. S. cerevisiae
has two genes encoding 14-3-3 proteins, BMH1 and BMH2 ;
and disruption of both genes is lethal [15]. A number of 14-3-3
isoforms from Arabidopsis complement this double disruption,
as does human 14-3-3d and a unique 14-3-3 protein from Dic-
tyostelium discoideum, indicating the conserved nature of 14-3-
3 function among di¡erent isoforms and di¡erent species [16].
A number of proteins that interact with mammalian type I
receptor have been identi¢ed by yeast two-hybrid screens;
none of these previously described interacting proteins were
found in our screen of a schistosome cDNA library employing
SmRK1 as bait. The immunophilin FKBP12 is the interacting
protein most commonly detected, however, SmRK1 lacks the
identi¢ed FKBP12 binding site, re£ecting the divergent nature
of this schistosome type I receptor [17]. Our identi¢cation of
14-3-3 as a type I receptor-interacting protein, yielded by a
schistosome library screen, may re£ect broad genomic di¡er-
ences between schistosomes and mammals. An interaction be-
tween TGFL receptors and 14-3-3 proteins has not previously
been reported, however results of a yeast complementation
study have suggested a role for 14-3-3 in TGFL signaling. S.
cerevisiae strain DS9-22, defective in inositol-1-phosphate syn-
thase and requiring myo-inositol for growth was comple-
mented by clones expressing human 14-3-3, TLRII and the
A subunit of protein phosphatase 2A; the BK protein phos-
phatase 2A subunit interacts with TLRI [18,19]. These results
suggest that all three proteins function in a common pathway.
TGFL is a potent inhibitor of cell cycle progression in many
cell types. 14-3-3 proteins also play a role in promoting cell
cycle arrest through binding Cdc25. Cdc25 de-phosphorylates
the cyclin-dependent kinase Cdc2, required for the initiation
of mitosis. 14-3-3 binding results in the cytoplasmic sequestra-
tion of Cdc25 and its ‘functional inactivation’, thus maintain-
ing cell cycle arrest [20]. PP2A also de-phosphorylates Cdc25,
and its function is regulated by the BK subunit, a protein
which also interacts with TLRI [21,19]. Interaction of
BKPP2A and 14-3-3 with TLRI, may provide a link between
TGFL receptor ligation and cell cycle arrest.
14-3-3 proteins have been shown to bind phophoserine res-
idues with the consensus binding sites RSXpSXP and RXY/
FXpSXP in many target proteins [10,11]. Recently, a number
of non-consensus 14-3-3 binding sites have also been reported
[10]. SmRK1 and TLRI contain neither a consensus motif nor
Fig. 4. S. mansoni 14-3-3O enhances TGFL-induced transcriptional
activation of p3TP-Lux. R1B cells were transiently transfected with
p3TP-Lux reporter, L-galactosidase construct and 0.3 Wg of the ex-
pression constructs pCMV5-TLRI-HA or pCMV2-14-3-3O-FLAG or
with both constructs; pCMV5-TLRI-HA (0.3 Wg) and increasing
amounts of pCMV2-14-3-3O-FLAG (0.1, 0.3 and 0.9 Wg). Cells were
subsequently incubated for 20 h in the presence of 500 pM TGFL
and relative luciferase activity was measured in cell lysates. Lucifer-
ase activity was normalized to L-galactosidase. Data are the mean
from triplicate determinations of a representative experiment.
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any other previously identi¢ed 14-3-3 binding sites. To deter-
mine whether phosphorylated residues are important in the
SmRK1^14-3-3O interaction, the ability of AP treated
SmRK1 to interact with 14-3-3O was ascertained. Concomi-
tant with a time-dependent de-phosphorylation of SmRK1, a
strong reduction in the amount of SmRK1 bound to 14-3-3O
was observed. However, AP treatment did not completely
abolish binding, suggesting either the incomplete removal of
phosphate or the presence of an additional phosphatase-in-
sensitive 14-3-3O binding site. SmRK1 contains at least one
novel 14-3-3 binding site, which is likely to include either
phosphoserine or phosphothreonine residues.
The 14-3-3O clone identi¢ed by SmRK1 screening encoded
only the C-terminal 38 amino acids of 14-3-3O, indicating that
this region is a binding site for SmRK1 and that the 14-3-3O
C-terminus is su⁄cient for SmRK1 binding. This is consistent
with the ¢nding that the 14-3-3 helix KI, which is retained
within the C-terminal 38 amino acids, has been shown to be
the region responsible for extensive interaction with phospho-
peptide [22], and interaction studies with human 14-3-3d have
shown the C-terminal 15 amino acids to be su⁄cient for e⁄-
cient binding of Cbl, Raf and phosphatidylinositol 3-kinase
(PI3K) [23].
14-3-3 proteins have been found in the majority of impor-
tant signaling pathways in cells, where they associate with a
number of key signaling proteins and cell cycle regulators.
These include Raf, PKC, MEKKs, PI3K, Bcr and Bcr-Abl,
Cdc25, A20 and BAD, although the functional consequence
of many 14-3-3^signaling protein interactions remains to be
de¢ned [13]. With the exception of Smads 2 and 3, which act
as downstream substrates of TLRI to activate transcription
activity, all previously identi¢ed TGFL receptor-interacting
proteins either have no e¡ect on TGFL-induced TLRI signal-
ing (K subunit of farnesyl transferase), or act to inhibit tran-
scription activity (FKBP12, BKPP2A, STRAP, TRAP and
TRIP-1) [19,24^26]. Conversely 14-3-3O acts to enhance
TGFL-induced signaling by TLRI.
In conclusion, conservation of 14-3-3’s interaction with
TLRIs from organisms as diverse as schistosomes and humans
indicates that 14-3-3 is likely to play a role in TGFL signal
transduction in most, if not all, animal species. We aim to
investigate the functional signi¢cance of the SmRK1^14-3-3
interaction in schistosomes.
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